Pharmacokinetics of apomorphine in parkinsonian patients.
Identifieur interne : 001699 ( PubMed/Curation ); précédent : 001698; suivant : 001700Pharmacokinetics of apomorphine in parkinsonian patients.
Auteurs : E. Nicolle [France] ; P. Pollak ; F. Serre-Debeauvais ; P. Richard ; C L Gervason ; E. Broussolle ; M. GavendSource :
- Fundamental & clinical pharmacology [ 0767-3981 ] ; 1993.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Apomorphine.
- chemical , pharmacokinetics : Apomorphine.
- metabolism : Parkinson Disease.
- Abdomen, Aged, Biological Availability, Drug Administration Schedule, Female, Humans, Injections, Intravenous, Injections, Subcutaneous, Male, Middle Aged, Thigh.
Abstract
Apomorphine, a dopamine agonist, has been used efficiently in parkinsonian patients to treat severe levodopa-induced on-off phenomenon. Motor improvement has been obtained both with continuous subcutaneous (SC) infusions, and multiple SC injections. So as to assist in the understanding of the clinical results, we studied the peripheral pharmacokinetics of apomorphine in 20 patients after intravenous (IV) or SC injections in the anterior abdominal wall and in the thigh at various doses, or SC infusion. Plasma apomorphine levels were measured by high-performance liquid chromatography with electrochemical detection. After an SC injection in the abdominal wall, the Tmax was brief (16 +/- 11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7 +/- 25.8 min). The AUC was similar following SC and IV injections, suggesting that apomorphine was completely absorbed from subcutaneous tissue. Inter-subject variability in drug absorption was large. We noticed a trend towards a more complete absorption following injection in the abdominal wall rather than in the thigh. In patients chronically treated by continuous SC infusion, the apparent plasma half-life was five times longer than that following SC or IV injections. These pharmacokinetic data may explain the rapid onset and brief duration of clinical effects, and the usefulness of individual titration for intermittent SC apomorphine injections, and the smoother motor response obtained with continuous SC infusions.
PubMed: 8370571
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001740
Links to Exploration step
pubmed:8370571Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacokinetics of apomorphine in parkinsonian patients.</title>
<author><name sortKey="Nicolle, E" sort="Nicolle, E" uniqKey="Nicolle E" first="E" last="Nicolle">E. Nicolle</name>
<affiliation wicri:level="1"><nlm:affiliation>Laboratoire de Pharmacologie, Centre Hospitalier Universitaire de Grenoble, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie, Centre Hospitalier Universitaire de Grenoble</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name>
</author>
<author><name sortKey="Serre Debeauvais, F" sort="Serre Debeauvais, F" uniqKey="Serre Debeauvais F" first="F" last="Serre-Debeauvais">F. Serre-Debeauvais</name>
</author>
<author><name sortKey="Richard, P" sort="Richard, P" uniqKey="Richard P" first="P" last="Richard">P. Richard</name>
</author>
<author><name sortKey="Gervason, C L" sort="Gervason, C L" uniqKey="Gervason C" first="C L" last="Gervason">C L Gervason</name>
</author>
<author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name>
</author>
<author><name sortKey="Gavend, M" sort="Gavend, M" uniqKey="Gavend M" first="M" last="Gavend">M. Gavend</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1993">1993</date>
<idno type="RBID">pubmed:8370571</idno>
<idno type="pmid">8370571</idno>
<idno type="wicri:Area/PubMed/Corpus">001740</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001740</idno>
<idno type="wicri:Area/PubMed/Curation">001699</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001699</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacokinetics of apomorphine in parkinsonian patients.</title>
<author><name sortKey="Nicolle, E" sort="Nicolle, E" uniqKey="Nicolle E" first="E" last="Nicolle">E. Nicolle</name>
<affiliation wicri:level="1"><nlm:affiliation>Laboratoire de Pharmacologie, Centre Hospitalier Universitaire de Grenoble, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie, Centre Hospitalier Universitaire de Grenoble</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name>
</author>
<author><name sortKey="Serre Debeauvais, F" sort="Serre Debeauvais, F" uniqKey="Serre Debeauvais F" first="F" last="Serre-Debeauvais">F. Serre-Debeauvais</name>
</author>
<author><name sortKey="Richard, P" sort="Richard, P" uniqKey="Richard P" first="P" last="Richard">P. Richard</name>
</author>
<author><name sortKey="Gervason, C L" sort="Gervason, C L" uniqKey="Gervason C" first="C L" last="Gervason">C L Gervason</name>
</author>
<author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name>
</author>
<author><name sortKey="Gavend, M" sort="Gavend, M" uniqKey="Gavend M" first="M" last="Gavend">M. Gavend</name>
</author>
</analytic>
<series><title level="j">Fundamental & clinical pharmacology</title>
<idno type="ISSN">0767-3981</idno>
<imprint><date when="1993" type="published">1993</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abdomen</term>
<term>Aged</term>
<term>Apomorphine (administration & dosage)</term>
<term>Apomorphine (pharmacokinetics)</term>
<term>Biological Availability</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Intravenous</term>
<term>Injections, Subcutaneous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (metabolism)</term>
<term>Thigh</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Apomorphine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Apomorphine</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Abdomen</term>
<term>Aged</term>
<term>Biological Availability</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Intravenous</term>
<term>Injections, Subcutaneous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Thigh</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Apomorphine, a dopamine agonist, has been used efficiently in parkinsonian patients to treat severe levodopa-induced on-off phenomenon. Motor improvement has been obtained both with continuous subcutaneous (SC) infusions, and multiple SC injections. So as to assist in the understanding of the clinical results, we studied the peripheral pharmacokinetics of apomorphine in 20 patients after intravenous (IV) or SC injections in the anterior abdominal wall and in the thigh at various doses, or SC infusion. Plasma apomorphine levels were measured by high-performance liquid chromatography with electrochemical detection. After an SC injection in the abdominal wall, the Tmax was brief (16 +/- 11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7 +/- 25.8 min). The AUC was similar following SC and IV injections, suggesting that apomorphine was completely absorbed from subcutaneous tissue. Inter-subject variability in drug absorption was large. We noticed a trend towards a more complete absorption following injection in the abdominal wall rather than in the thigh. In patients chronically treated by continuous SC infusion, the apparent plasma half-life was five times longer than that following SC or IV injections. These pharmacokinetic data may explain the rapid onset and brief duration of clinical effects, and the usefulness of individual titration for intermittent SC apomorphine injections, and the smoother motor response obtained with continuous SC infusions.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8370571</PMID>
<DateCreated><Year>1993</Year>
<Month>10</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted><Year>1993</Year>
<Month>10</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0767-3981</ISSN>
<JournalIssue CitedMedium="Print"><Volume>7</Volume>
<Issue>5</Issue>
<PubDate><Year>1993</Year>
</PubDate>
</JournalIssue>
<Title>Fundamental & clinical pharmacology</Title>
<ISOAbbreviation>Fundam Clin Pharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>Pharmacokinetics of apomorphine in parkinsonian patients.</ArticleTitle>
<Pagination><MedlinePgn>245-52</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Apomorphine, a dopamine agonist, has been used efficiently in parkinsonian patients to treat severe levodopa-induced on-off phenomenon. Motor improvement has been obtained both with continuous subcutaneous (SC) infusions, and multiple SC injections. So as to assist in the understanding of the clinical results, we studied the peripheral pharmacokinetics of apomorphine in 20 patients after intravenous (IV) or SC injections in the anterior abdominal wall and in the thigh at various doses, or SC infusion. Plasma apomorphine levels were measured by high-performance liquid chromatography with electrochemical detection. After an SC injection in the abdominal wall, the Tmax was brief (16 +/- 11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7 +/- 25.8 min). The AUC was similar following SC and IV injections, suggesting that apomorphine was completely absorbed from subcutaneous tissue. Inter-subject variability in drug absorption was large. We noticed a trend towards a more complete absorption following injection in the abdominal wall rather than in the thigh. In patients chronically treated by continuous SC infusion, the apparent plasma half-life was five times longer than that following SC or IV injections. These pharmacokinetic data may explain the rapid onset and brief duration of clinical effects, and the usefulness of individual titration for intermittent SC apomorphine injections, and the smoother motor response obtained with continuous SC infusions.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nicolle</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Laboratoire de Pharmacologie, Centre Hospitalier Universitaire de Grenoble, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pollak</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Serre-Debeauvais</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Richard</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gervason</LastName>
<ForeName>C L</ForeName>
<Initials>CL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Broussolle</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gavend</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Fundam Clin Pharmacol</MedlineTA>
<NlmUniqueID>8710411</NlmUniqueID>
<ISSNLinking>0767-3981</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber>
<NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000005" MajorTopicYN="N">Abdomen</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001058" MajorTopicYN="N">Apomorphine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007275" MajorTopicYN="N">Injections, Intravenous</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013848" MajorTopicYN="N">Thigh</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year>
<Month>1</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1993</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1993</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">8370571</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001699 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001699 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:8370571 |texte= Pharmacokinetics of apomorphine in parkinsonian patients. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:8370571" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |